Healthcare machine learning is highly sensitive to the way data and evaluation pipelines are constructed.
Two teams can use similar algorithms and obtain substantially different results because of differences in cohort definition, preprocessing, feature availability, outcome labeling, missing-data handling, temporal splitting, hyperparameter selection, or evaluation strategy.
This creates a reproducibility challenge.
A reported performance metric is only as meaningful as the methodology behind it.
For healthcare AI, reproducibility should begin with clear documentation of the data-generating context and continue through preprocessing, feature construction, model development, validation, and evaluation.
Temporal considerations are particularly important.
A model intended for prospective clinical use should not be evaluated using information that would only become available after the prediction point. Otherwise, the reported performance may not represent the real decision environment.
Reproducible pipelines also make independent validation easier.
Another team can examine the methodology, identify assumptions, test the system on an appropriate dataset, and investigate differences in performance.
Commercial systems introduce additional constraints because vendors may protect proprietary models and infrastructure. However, proprietary status does not eliminate the need for evidence.
Healthcare organizations can still require documentation of validation populations, evaluation methodology, known limitations, update procedures, and appropriate independent testing.
The objective is not perfect scientific openness.
The objective is credible evidence.
A healthcare AI system should be able to withstand reasonable scrutiny before it is entrusted with consequential decisions.
Top comments (0)